Results of a randomized controlled trial presented at Diabetes Canada's 2019 Professional Conference demonstrate the clinical value of the novel SiteSmart™ pen needles educational concept. MONTREAL, Oct. 4, 2019 /PRNewswire/ -

IRVINE, Calif., Oct. 4, 2019 /PRNewswire/ -- Griffin-American Healthcare REIT III, Inc. announced today that its board of directors has approved an updated estimated per share net asset value ("NAV") of its common stock of $9.40 calculated as of June 30, 2019. Previously, on Oct. 5, 2

STOCKHOLM, Oct. 4, 2019 /PRNewswire/ -- RaySearch has received a new regulatory clearance from the Chinese authorities NMPA (previously CFDA) for the treatment planning system RayStation®. With this clearance RaySearch can continue to supply the innovative and machine agnostic RayStation to customers in China. RayStation

SUZHOU, China, Oct. 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced today that it has agreed to place 97,000,000 new shares (the "Placing

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its IND application for TJD5, a novel CD73 antib

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common sto

NEWARK, N.J., Oct. 3, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $4.9 million and a loss per share of $0.35 for the fiscal year ended July 31, 2019. Fourth quarter revenue was $1.4 million and the los

AUSTIN, Texas, Oct. 3, 2019 /PRNewswire/ -- Today, the president of the American Association of Nurse Practitioners (AANP), Sophia L. Thomas, issued the following statement regarding President Trump's executive order, entitled Protecting and Improving Medicare for our Nation's Seniors.   

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced that it has entered into a global, m

WINNIPEG, Oct. 3, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJD.PK), a cardiovascular pharmaceutical company, is pleased to announce that it has reached a preferred pricing agreement with the AIDS Drug Assistance Program (ADAP) Crisis Task Force for ZYPITAMAGTM (pitavastatin) tablets. The agreement will